VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Significant Decline in Short Interest

VivoSim Labs, Inc. (NASDAQ:VIVS) was the recipient of a large drop in short interest in the month of June. As of June 15th, there was short interest totaling 19,972 shares, a drop of 40.1% from the May 31st total of 33,344 shares. Currently, 0.8% of the shares of the company are short sold. Based on an average daily trading volume, of 58,969 shares, the short-interest ratio is presently 0.3 days.

Institutional Trading of VivoSim Labs

An institutional investor recently bought a new stake in VivoSim Labs stock. Two Sigma Investments LP acquired a new position in shares of VivoSim Labs, Inc. (NASDAQ:VIVS) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned 0.89% of VivoSim Labs as of its most recent SEC filing. Institutional investors and hedge funds own 8.23% of the company’s stock.

VivoSim Labs Price Performance

NASDAQ:VIVS traded down $0.04 during trading hours on Wednesday, reaching $1.03. 45,787 shares of the company were exchanged, compared to its average volume of 855,817. The business has a 50 day moving average of $1.28 and a 200 day moving average of $1.69. VivoSim Labs has a 1-year low of $0.94 and a 1-year high of $5.30. The company has a market capitalization of $2.70 million, a P/E ratio of -0.33 and a beta of 1.38.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded shares of VivoSim Labs from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

About VivoSim Labs

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.